A new Lancet review finds current mRNA vaccines safe, highly effective, and with potential to broaden use beyond COVID-19 to influenza, RSV, cancer, and autoimmune diseases.

Serious adverse events are rare; myocarditis or pericarditis mainly follow the second dose in young males, but overall risk remains lower than the risk from a COVID-19 infection.

Vaccine effectiveness is strong in the short term, with about 87% protection against documented infection, 93% against hospitalization, and 94% against death within 14 to 42 days post-vaccination; protection wanes over time but boosters restore much of it.

To reach full impact, the review calls for ongoing innovation in storage, distribution, cost reduction, and robust safety monitoring, plus sustained investment and policies to ensure global access and preparedness.

The review stresses platform limitations and the critical role of public trust, noting misinformation and reliance on voluntary reporting systems can undermine uptake, alongside the politicization of vaccine discourse and the need for ongoing safety surveillance.

Boosters are essential for maintaining protection, especially against newer variants, with emphasis on continuing safety monitoring and real-world data.

Transparency in safety data sharing and robust real-world surveillance are vital as vaccines evolve and new variants emerge.

Expanding manufacturing capacity and achieving equitable access in low- and middle-income countries is crucial, with recommendations for technology transfer, local production, and strong regulatory systems to shorten supply chains and cut costs.

Trust, access, and equity are central themes, as uptake varies due to misinformation and past mistrust; the authors advocate transparent safety communication and evidence-based information.

The authors call for sustained innovation, global collaboration, and continued post-licensure safety monitoring to maximize life-saving benefits while noting differences across populations, products, and data collection, and the evolving virus.

Results come from diverse countries and programs, so outcomes may vary by population, product, and data methods, and ongoing viral evolution could affect effectiveness.

The evidence base includes randomized trials, surveillance, and active pharmacovigilance, detailing vaccine components, manufacturing quality controls, and regulatory standards that underpin safety and effectiveness.